Results 121 to 130 of about 135,997 (338)
Neurourology and Urodynamics, EarlyView.ABSTRACT Introduction Refractory neurogenic lower urinary tract dysfunction presents an obstinate clinical problem. For patients who fail nonsurgical measures, we advocate for bladder‐sparing, continent urinary diversion as the optimal approach to management.
Brian W. Chao, Sean P. Elliott
wiley +1 more source
A botulinum toxin farmakológiai felhasználásának lehetőségei
, 2017 A botulinum toxin egy rendkívül erélyes neurotoxin, melyet a Gram-pozítív anaerob spóraképző Clostridium botulinum termel. A toxinnak nyolc szerológiailag eltérő típusát különböztetjük meg az A, B, C (C1, C2), D, E, F, G és H, melyek eltérő antigén ...
Tolnai, Réka
core
“What Medical Management Should Be First Line for Bladder Storage Symptoms in NLUTD”—Pro Botox
Neurourology and Urodynamics, EarlyView.ABSTRACT Objectives Neurogenic lower urinary tract dysfunction (NLUTD) severely impairs patient quality of life (QoL). While oral medications are often first‐line treatments, their high failure rates and side effects limit their effectiveness. Thus, we argue for the use of intravesical botulinum toxin A (BoNT‐A) injections as a first‐line alternative ...
Vada Furlan +2 more
wiley +1 more source
Therapeutic Use of Botulinum Toxin in Neurology: a Literature Review
Botulinum toxin (BTX), a neurotoxin produced by Gram-positive Clostridium botulinum, is widely known for its broad application in aesthetic medicine, but it is also playing an increasingly important therapeutic role in neurology.
Natalia Skrzypska +5 more
core +1 more source
Expanding the Phenotype of PARK‐PRKN to Spastic Paraplegia: A Report of Two Cases
Movement Disorders Clinical Practice, EarlyView.
Nicolas Geoffre +5 more
wiley +1 more source
Neurourology and Urodynamics, EarlyView.ABSTRACT Background & Aims Neurogenic lower urinary tract dysfunction (NLUTD) can produce bothersome urinary symptoms, impact quality of life, and in some cases, lead to deterioration of upper urinary tract function. Intradetrusor injection of onabotulinumtoxin‐A (BoNT‐A) is approved for NLUTD in patients who have an inadequate response to or ...
Shirley L. Wang +2 more
wiley +1 more source
From Toxin to Treatment: A Narrative Review on the Use of Botulinum Toxin for Autonomic Dysfunction
ToxinsSince its regulatory approval over a half-century ago, botulinum toxin has evolved from one of the most potent neurotoxins known to becoming routinely adopted in clinical practice.
Lucas Rempel +5 more
doaj +1 more source
Neurourology and Urodynamics, EarlyView.ABSTRACT Objective To synthesize the evidence on the efficacy and safety of mirabegron and intradetrusor onabotulinumtoxinA (BoNT‐A) as separate interventions for overactive bladder (OAB) in Parkinson's disease (PD). Methods A systematic review and meta‐analysis with parallel synthesis of two distinct interventions was conducted of randomized and ...
Hussain Arshad +4 more
wiley +1 more source
Neurourology and Urodynamics, EarlyView.ABSTRACT Purpose To evaluate the safety, procedural feasibility, and pilot clinical outcomes for a new implanted device delivering adaptive pudendal nerve stimulation. Materials and Methods Thirteen adult women with treatment‐refractory mixed (n = 8) or urge (n = 5) urinary incontinence were implanted with a Picostim‐DyNeuMo system incorporating an ...
Siemen Herroelen +8 more
wiley +1 more source
Urodynamic Voiding Patterns in Multiple Sclerosis
Neurourology and Urodynamics, EarlyView.ABSTRACT Aims This study aimed to describe urodynamic voiding patterns in patients with MS (PwMS) using standardized assessments, and to compare the performance of the available nomograms and indices for obstruction and bladder contractility. Methods PwMS and lower urinary tract symptoms underwent cystometry and pressure flow studies.
Camille Chesnel +5 more
wiley +1 more source